1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
RANI
Event Date
2021-07-30
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
$11.00-$11.00
Shares Offered
6.67M
24.39M
$717.8M
27.3%
Implied Upside vs Midpoint
Description
We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage. Patient aversion to injections has promoted a significant interest in the development of solutions to enable the oral delivery of biologics. Despite repeated attempts, oral delivery of biotherapeutics remains largely unsuccessful due to their rapid degradation and digestion in the GI environment. The most significant hurdle for oral biologics is the ability to achieve sufficient bioavailability, which is the proportion of a delivered dose that reaches the bloodstream and produces an intended therapeutic effect. Most prior attempts have taken a chemistry-based approach, which involves protecting the biologic from being digested and improving absorption by chemical agents. The best attempts have resulted in low bioavailability of peptides in the range of 1% or less. In contrast to these prior attempts, the RaniPill capsule delivers biologics with high bioavailability, similar to subcutaneous injection, in the range of 40% to 78%, with high dosing accuracy. Further, the RaniPill capsule is designed to orally deliver a number of biologics, from peptides to antibodies. We also believe our technology may have application in delivering emerging cell and gene therapies. The RaniPill capsule’s proprietary protective coating is designed to withstand the stomach acid and only dissolve in the jejunum, the upper half of the small intestine. Once dissolved, a microneedle containing a biologic drug is delivered into the highly vascularized wall of the small intestine so that the biologic can enter the bloodstream. We have tested our most advanced product candidate in a Phase 1 clinical trial conducted in Australia, and we are further optimizing the formulation in preparation for a regulatory submission to FDA to initiate subsequent trials. Based on discussions with the FDA and the guidance we have received from CDRH in a pre-IDE meeting, we expect to be able to conduct further testing in humans in the contemplated IDE study of the RaniPill in the United States. In this study, we will evaluate the safety and tolerability of the RaniPill capsule, independent of any drug or biologic. This will be followed by a more standard regulatory pathway for each of our pipeline candidates. Our current pipeline includes well-characterized biologics that have been in clinical use for several years. We believe that we may be able to leverage the FDA’s prior conclusions of safety, purity and potency for certain approved biologic products in our own BLA submissions. The degree to which we may be able to reduce the burden on our own development will depend on whether the API is the same as the original approved product, particularly for products originally approved as NDAs and now deemed to be biologics. We intend to have this clarified on a product-by-product basis in pre-IND meetings with the FDA. --- Our office is located at 2051 Ringwood Avenue, San Jose, California 95131. Our telephone number is 408-457-3700. Our website address is www.ranitherapeutics.com.
Rani Therapeutics Holdings, Inc. annual income statement and balance sheet, FY 2021 to FY 2025, as reported in SEC filings.
| Metric | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Revenue | $2.7M | — | $1.0M | $1.6M |
| Operating income | ($51.6M) | ($63.5M) | ($53.3M) | ($38.3M) |
| Net income | ($8.3M) | ($30.6M) | ($30.0M) | ($29.7M) |
| Metric | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Total assets | $124M | $108M | $36.6M | $58.6M |
| Total liabilities | $2.6M | $34.0M | $33.1M | $17.1M |
| Total equity | $122M | $74.0M | $3.5M | $41.5M |
| Cash & equivalents | $117M | $27.0M | $3.8M | $18.6M |